Fusion Antibodies – results argue “significant progress”, so why more than 7% share price decline?...
By Steve Moore | Tuesday 10 August 2021
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Fusion Antibodies (FAB) has announced results for its year ended 31st March 2021 emphasising “significant progress with sustained revenue growth, progress on the R&D pipeline, and continue to expand our range of services”. So why are the shares, at 125p, currently more than 7% lower in response?…
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.